Full-Time

Access and Reimbursement Manager

Access & Reimbursement

Posted on 10/6/2025

Mallinckrodt

Mallinckrodt

1,001-5,000 employees

Specialty pharmaceutical developer, manufacturer, distributor

No salary listed

Jackson, MS, USA + 1 more

More locations: Memphis, TN, USA

In Person

Local travel: some overnight required, may vary depending on the region.

Category
Sales & Account Management
Requirements
  • Minimum of 5 years’ experience working with specialty pharmaceutical products, or minimum of 2 years’ access-related position outside of pharma
  • Strong understanding of insurance and benefit design with both commercial and government payers
  • Background in Access & Reimbursement, Payer account management, Specialty Pharmacy distribution, Patient Services, Case Management
  • Successful navigation of complex authorization processes for specialty medications
  • Working with a Patient Service Center/Hub in order to design case-specific strategies based on payer mix, benefit design, and authorization requirements
  • Coordinating case pull-through with the Patient Service Center, Case Managers, Sales, and Specialty Pharmacies
  • Demonstrated analytical, problem solving, and relationship-building skills
  • Excellent communication, organizational and leadership skills
  • Customer interaction and field travel up to 60% - overnights dependent on geography
Responsibilities
  • Lead the case 'pull-through' process on open cases
  • Identify payer trends and alert business partners
  • Develop, coordinate, and execute tactical plans to create and maintain treatment access for patients
  • Facilitate communication with prescribing offices, contracted Specialty Pharmacies, the Patient Service Center, and sales colleagues
  • Support and educate HCP offices on best practices that streamline the authorization process and expedite treatment access for patients
  • Communicate with Specialty Pharmacies to improve processing time and help facilitate shipment scheduling
Desired Qualifications
  • Experience working with a Patient Service Center/Hub
  • Experience in field responsibilities that include supporting and educating HCP offices
  • Experience in coordinating case pull-through with various stakeholders

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Simplify Jobs

Simplify's Take

What believers are saying

  • Merger with Endo completed, forming NYSE-listed therapeutics leader by Q4 2025.
  • Reduced debt 47% to $865.6M and grew Acthar Gel sales 14.2% in 2024.
  • Sold Therakos for $925M, optimizing portfolio for specialty pharmaceuticals.

What critics are saying

  • Endo merger integration disrupts operations, overloading with $6.7B debt.
  • Therakos sale drops immunotherapy revenue, losing edge to Amgen immediately.
  • Acthar Gel's $300K pricing triggers DOJ probe and $500M fines within 18 months.

What makes Mallinckrodt unique

  • Mallinckrodt specializes in Acthar Gel for autoimmune diseases over 150 years.
  • Focuses on rare diseases and critical care therapies for underserved patients.
  • Launched Acthar Gel self-injectable to improve patient adherence and convenience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Relocation Assistance

Company News

PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.

Stock Titan
Aug 1st, 2025
Mallinckrodt-Endo Merger Creates Therapeutics Leader

Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.

The Business Journals
Jul 25th, 2025
Mallinckrodt Reaches $7B Merger Milestone

Mallinckrodt has reached a milestone in a $7 billion merger deal.

Sharecast
Mar 13th, 2025
Mallinckrodt and Endo to merge in $6.7bn deal

Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.

INACTIVE